Efficacy and safety of modified tetracycline dosing in a quadruple therapy for Helicobacter pylori: A retrospective single center study

Table 1 Demographic and clinical data of patients according to eradication outcome

Outcome	Successful	Failed	P
N	365	29
Age (mean ± SD)	45.90 ± 13.95	52.5 ± 12.2	0.319
Age range	(20-77)	(27-68)
Age (≤ 50)	221	15	0.046
Gender (M/F)	122/243	44/74	0.685
Smoking (Yes/No)	31/334	5/29	0.168
Drinking (Yes/No)	61/304	8/29	0.138
Education			0.099
Primary school	61	19
Middle school	138	40
College	158	57
GC family history			0.361
Yes/No	15/350	2/27
Endoscopy diagnosis			0.597
Gastritis	247	22
Ulcer	45	2
Unknown	73	5
Intestinal metaplasia			0.557
No	176	17
Yes	113	7
Unknown	76	5
Treatment			0.959
500 mg b.i.d.	145	12
750 mg b.i.d.	110	8
500 mg t.i.d.	110	9
Treatment line1			0.026
First line	291	18
Rescue therapy	74	11
PPI			0.762
Pantoprazole	151	14
Esomeprazole	69	4
Rabeprazole	139	11
Lansoprazole	6	0
Bismuth			0.351
Bismuth potassium citrate	302	22
Colloidal bismuth pectin	63	7
Type 2 diabetes	18	6	0.020
Hypertension	48	15	< 0.0001
Hyperlipidemia	19	7	< 0.0001
Penicillin allergy	70	6	0.843

¹Recording this treatment as start of frequency. Rescue therapy was defined as patients who had eradicated therapy once or more but failed.

P values were from two-side comparisons the differences between two groups. M: male; F: female; 500 mg b.i.d.: Tetracycline twice daily; 750 mg b.i.d.: Tetracycline twice daily; 500 mg t.i.d.: Tetracycline three times daily.

Table 2 Treatment times previously of the enrolled patients and its eradication rates

Treatment times	500 mg b.i.d.	750 mg b.i.d.	500 mg t.i.d.
1	93.4% (127/136)	97.5% (77/79)	92.6% (87/94)
2	83.3% (15/18)	87.5% (28/32)	90.9% (20/22)
≥ 3	100% (3/3)	71.4% (5/7)	100% (3/3)
Rescue therapy1	85.7% (18/21)	84.6% (33/39)	92.0% (23/25)

¹Rescue therapy was defined as patients who had eradicated therapy once or more but failed.

500 mg b.i.d.: Tetracycline twice daily; 750 mg b.i.d.: Tetracycline twice daily; 500 mg t.i.d.: Tetracycline three times daily.

Table 3 Penicillin allergy of the enrolled patients and its intention-to-treat eradication rates

Penicillin allergy	500 mg b.i.d.	750 mg b.i.d.	500 mg t.i.d.
Yes	91.7% (22/24)	95.5% (21/22)	90.0% (27/30)
No	92.5% (123/133)	92.7% (89/96)	93.3% (83/89)

500mg b.i.d.: Tetracycline twice daily; 750 mg b.i.d.: Tetracycline twice daily; 500 mg t.i.d.: Tetracycline three times daily.

Table 4 Drug adverse events in different treatment groups (n/N)

Group	500 mg b.i.d.	750 mg b.i.d.	500 mg t.i.d.	All	P
Taste distortion	2	6	8	16	0.060
Nausea	2	6	4	12	0.190
Abdominal pain	1	2	0	3	0.320
Vomiting	0	1	0	1	0.310
Bloating	3	0	1	4	0.290
Diarrhea	4	2	1	7	0.570
Dizziness	1	2	1	4	0.670
Skin rash	3	4	3	10	0.740
Fatigue	1	4	1	6	0.140
Fever	4	6	8	18	0.250
Constipation	1	1	0	2	0.630
Decreased appetite	0	3	7	10	0.009
Chills	0	1	0	1	0.310
Melena	0	0	1	1	0.310
Abdominal discomfort1	2	0	1	3	0.480
All2	15.3% (24/157)	32.3% (38/118)	30.3% (36/119)	98/394	0.002

¹Abdominal discomfort, but not of specified.

²The symptoms of a single adverse reaction are counted as 1, and a patient may have multiple adverse events.

P values were from two-side comparisons the differences among three treatment group. N: Total patient number; n: Patient number with side effects; 500 mg b.i.d.: Tetracycline twice daily; 750 mg b.i.d.: Tetracycline twice daily; 500 mg t.i.d.: Tetracycline three times daily.